Literature DB >> 15230296

The role of CD40 ligand in systemic lupus erythematosus.

J Yazdany1, J Davis.   

Abstract

CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expression of CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although murine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15230296     DOI: 10.1191/0961203304lu1030oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

Review 1.  Platelet CD40L at the interface of adaptive immunity.

Authors:  Bennett D Elzey; Timothy L Ratliff; Jennifer M Sowa; Scott A Crist
Journal:  Thromb Res       Date:  2010-11-13       Impact factor: 3.944

Review 2.  New therapies for systemic lupus erythematosus.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

3.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 4.  Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.

Authors:  E Kassi; P Moutsatsou
Journal:  J Biomed Biotechnol       Date:  2010-06-10

Review 5.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Chary López-Pedrera; Maria Ángeles Aguirre; Nuria Barbarroja; Maria José Cuadrado
Journal:  J Biomed Biotechnol       Date:  2010-09-26

6.  Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype.

Authors:  Ameet A Chimote; Peter Hajdu; Leah C Kottyan; John B Harley; Yeoheung Yun; Laura Conforti
Journal:  J Autoimmun       Date:  2016-03-16       Impact factor: 7.094

7.  Early growth response-1 (EGR-1) and nuclear factor of activated T cells (NFAT) cooperate to mediate CD40L expression in megakaryocytes and platelets.

Authors:  Scott A Crist; Bennett D Elzey; Michelle T Ahmann; Timothy L Ratliff
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

8.  Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes.

Authors:  Scott A Crist; Daniel L Sprague; Timothy L Ratliff
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

9.  T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus.

Authors:  Ying Zhou; Jun Yuan; Yujun Pan; Yiping Fei; Xiangning Qiu; Nan Hu; Yongqi Luo; Wenzhi Lei; Yaping Li; Hai Long; Amr H Sawalha; Bruce Richardson; Qianjin Lu
Journal:  Clin Immunol       Date:  2009-06-10       Impact factor: 3.969

10.  Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.

Authors:  Silvia Piantoni; Francesca Regola; Stefania Masneri; Michele Merletti; Torsten Lowin; Paolo Airò; Angela Tincani; Franco Franceschini; Laura Andreoli; Georg Pongratz
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.